BIO-THERA
68817717.110.18% ( +0.03 )
BIO-THERA (688177)
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye...
- Open
- 17.18
- High
- 17.50
- Low
- 17.07
- Prev. Close
- 17.08
- Volume
- 28.58K
- Turnover
- 49.40M
- Avg Price
- 17.28
- Bid/Ask Ratio
- --
- Amplitude
- 2.52%
- 52wk High
- 36.32
- Volume Ratio
- 0.67
- Turnover Ratio
- 0.69%
BIO-THERA Analyst Rating
View MoreForecast & Rating
Jan 6, 2026Price forecast
¥36.20111.57%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- WorldPharmaceuticals · Jul 24 at 04:10 AM
Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013
- Yicai · May 19 at 03:45 AM
China's Bio-Thera Gets US Nod for Golimumab Biosimilar
- PR Newswire · May 18 at 07:00 AM
Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
- Wallstreetcn · Feb 23 at 03:01 AM
Baili Tianheng's iza-bren late-stage triple-negative breast cancer Phase III clinical study achieved dual endpoints of PFS and OS
- prnewswire · Dec 12, 2025 at 04:34 AM
05:33 ET Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
- Zhitong · Oct 28, 2025 at 08:07 AM
BIO-THERA released its performance for the first three quarters, with a net loss attributable to the parent company of 224 million yuan
